Biolegend, 103155, Brilliant Violet 605™ anti-mouse CD45 Antibody, 50μg

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining with µg, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For flow cytometric staining with µl, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45. Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).
Application References(PubMed link indicates BioLegend citation): Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC) Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP) Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC) Seaman WE. 1983. J. Immunol. 130:1713. (CMCD) Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC) Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed Liu F, et al. 2012. Blood. 119:3295. PubMed Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Wong P, et al. 2021. STAR Protoc. 2:100262. PubMed Dalmas E et al. 2017. Immunity. 47(5):928-942 . PubMed Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed Zhao L, et al. 2022. Oncogene. 41:4200. PubMed Roweth HG, et al. 2022. Sci Adv. 8:eabo5224. PubMed Wang C, et al. 2023. iScience. 26:106272. PubMed Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed Santharam MA, et al. 2023. Int J Mol Sci. 24:. PubMed De C, et al. 2023. JCI Insight. 8:. PubMed Liu J, et al. 2023. Nat Commun. 14:2806. PubMed Mulcrone PL, et al. 2023. Sci Rep. 13:8436. PubMed Prior JT, et al. 2023. NPJ Vaccines. 8:80. PubMed Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed Liang J, et al. 2021. Cancer Manag Res. 13:6977. PubMed Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed Zhu Y, et al. 2022. Nat Commun. 13:4282. PubMed Chaurio RA, et al. 2022. Immunity. 55:115. PubMed Krishnamurty AT, et al. 2022. Nature. 611:148. PubMed Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed Zhu X, et al. 2023. Front Immunol. 14:1114802. PubMed Hettwer J, et al. 2022. Cardiovasc Res. 118:2778. PubMed Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed Michalaki C, et al. 2022. Curr Protoc. 2:e505. PubMed Israelow B, et al. 2020. bioRxiv. . PubMed Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed Boyd DF, et al. 2020. Nature. 587:466. PubMed Dando SJ, et al. 2021. Invest Ophthalmol Vis Sci. 62:10. PubMed Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed Zou C, et al. 2020. Cell Rep. 33:108447. PubMed Marinaccio C, et al. 2021. Cancer Discovery. 11(6):1398-1410. PubMed Lee J, et al. 2020. Gut Microbes. 1:. PubMed Barry KC, et al. 2018. Nat Med. 24:1178. PubMed Turner JA, et al. 2020. Immunity. 53:1202. PubMed Khamissi FZ, et al. 2022. Sci Adv. 8:eabm5900. PubMed Gao Y, et al. 2020. Nat Cell Biol. 1064:22. PubMed Shao Y, et al. 2019. Diabetes. 68:2131. PubMed Huai W, et al. 2019. J Exp Med. 216:772. PubMed Chen JC et al. 2018. Cell systems. 7(1):92-103 . PubMed Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed AR P, et al. 2016. Circ Res. 118: 400-409. PubMed Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed Lu SX, et al. 2021. Cell. . PubMed García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed Grizotte–Lake M, et al. 2018. Immunity. 49:1103. PubMed Skibba ME, et al. 2021. Respir Res. 22:315. PubMed Sharma S, et al. 2015. J Immunol. 194:5529. PubMed Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed Kuhn NF, et al. 2020. Nat Commun. 4.74375. PubMed Nording H, et al. 2021. Nat Commun. 12:3352. PubMed Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed Payne K, et al. 2016. J Leukoc Biol. 100: 625 - 635. PubMed Wagner JA, et al. 2020. Cell Rep. 31:107720. PubMed Freemerman AJ, et al. 2019. J Immunol. 202:1265. PubMed Celik H, et al. 2021. Cancer Discov. 11:3126. PubMed Sharma D, et al. 2022. Commun Biol. 5:479. PubMed Reddy A, et al. 2020. Cell. 183:62. PubMed Cortez-Toledo O, et al. 2017. PLoS One. 12(2):e0171268. PubMed Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Ganguly K, et al. 2022. Front Immunol. 13:930449. PubMed Bunting MD, et al. 2022. Sci Adv. 8:eabk3327. PubMed Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed Gkountela S et al. 2019. Cell. 176(1-2):98-112 . PubMed Kakizaki M, Watanabe R 2017. Neuropathology. 10.1111/neup.12386. PubMed Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed Wei W, et al. 2022. mSystems. 7:e0046922. PubMed Baik JE, et al. 2022. Clin Transl Med. 12:e758. PubMed Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed Reese B, et al. 2020. J Immunol. 205:3218. PubMed Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed Chen YG, et al. 2020. Molecular Cell. 76(1):96-109. PubMed Wolf KG, et al. 2022. JVS Vasc Sci. 3:336. PubMed Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed Gubin MM, et al. 2018. Cell. 175:1014. PubMed Di Mitri D, et al. 2019. Cell Rep. 28:2156. PubMed Bhattacharya A, et al. 2018. Neuropsychopharmacology. 43:2586. PubMed Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed Li J, et al. 2022. Nat Commun. 13:4032. PubMed Dulken BW, et al. 2019. Nature. 571:205. PubMed Gyoneva S, et al. 2019. Life Sci Alliance. 2:e201900453. PubMed Zhang Y, et al. 2019. Nat Commun. 10:3667. PubMed Myers DR, et al. 2020. Front Immunol. 11:576310. PubMed Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed Kang YH, et al. 2019. Nat Commun. 10:912. PubMed McDonald LT, et al. 2017. PLoS One. 12:e0180724. PubMed Terp MG, et al. 2021. Mol Oncol. 15:3299. PubMed Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed Berrien–Elliott MM, et al. 2020. Immunity. 51(3):479-490. PubMed Chen M, et al. 2019. Cell Stem Cell. 25:501. PubMed Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed Bennion BG, et al. 2019. J Virol. 93. PubMed Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed Pavelko K, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01532. PubMed Olson CA, et al. 2021. Cell Host Microbe. 29:1378. PubMed Ren J, et al. 2021. JCI Insight. 6:. PubMed Yin X, et al. 2020. Cell Rep. 33:108278. PubMed Becattini S, et al. 2021. Cell Host Microbe. 29(3):378-393.e5. PubMed Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed Molgora M, et al. 2020. Cell. 182:886. PubMed Hong JP, et al. 2020. Cell Reports Medicine. 1(3):100035. PubMed Fedele C, et al. 2021. J Exp Med. 218: . PubMed Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed Castillo–Azofeifa D, et al. 2019. EMBO J. 38:e99984. PubMed Teng F, et al. 2021. Cell Rep. 37:110051. PubMed Li H, et al. 2022. iScience. 25:104481. PubMed Perez-Cruz M, et al. 2021. PLoS One. e0236216:16. PubMed Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed Lloyd AF, et al. 2019. Nat Neurosci. 1.643055556. PubMed Shao Y, et al. 2019. Stem Cells. 37:1331. PubMed Lee A, et al. 2022. Nat Commun. 13:549. PubMed Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed Kuhn NF et al. 2019. Cancer cell. 35(3):473-488 . PubMed
RRID: AB_2562341 (BioLegend Cat. No. 103139) AB_2650656 (BioLegend Cat. No. 103155) AB_2562342 (BioLegend Cat. No. 103140)
Structure: Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution: All hematopoietic cells except mature erythrocytes and platelets
Function: Phosphatase, T and B cell activation
Ligand/Receptor: Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type: B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family: CD Molecules
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85. 3. Kishihara K, et al. 1993. Cell 74:143. 4. Pulido R, et al. 1988. J. Immunol. 140:3851.
Gene ID: 19264
UniProt: View information about CD45 on UniProt.org
Clone: 30-F11
Regulatory Status: RUO
Other Names: T200, Ly-5, LCA
Isotype: Rat IgG2b, κ